Fundraising Fox
🦊/Companies
Sign in

Tolerance Bio

Philadelphia, US · Founded 2023 · Delaware corporation · 17 employees on LinkedIn · 6 known investors

Find your way into Tolerance Bio

244 people in our graph share verified history with the Tolerance Bio team — schools, employers, funds. One of them is your warm intro.

Karthik Ardhanareeswaranunlockedknows Francisco Leon · together at Johnson & Johnson (overlapped)
×5knows the team · via Universidad Autónoma de Madrid
×6knows the team · via Johnson & Johnson

Tolerance Bio develops therapeutics targeting the thymus—the regulator of immune tolerance—to preserve, restore, and manipulate its function and extend health span. Its work includes iPSC-derived thymic organoids and licensed interleukin-7 therapy aimed at improving thymic function and immune resilience.

BiotechDeep TechLongevity

Founders & leadership

Tolerance Bio was founded in 2023 by Francisco Leon.

FLFrancisco Leon
Francisco LeoninFounder, CEO, ChairmanFrancisco Leon is an immunologist who co-founded Provention Bio (acquired by Sanofi in 2023), where he served as Chief Scientific Officer, and Celimmune (acquired by Amgen in 2017), where he served as Chief Medical Officer and Chief Executive Officer. His expertise spans immunodeficiencies, allergy, infectious diseases, immuno-oncology, transplantation, and autoimmunity, with extensive experience in drug development and clinical trial design across academic and pharmaceutical settings.
PB
Philip BallExecutive
JV
Justin VogelinFounding Team Member, CFO, Director

Board

DT
Damia Tormo CarullaBoard director
PCPablo Cironi
Pablo CironiinBoard MemberManaging Director at Criteria Bio Ventures
RG
Robert GoldsteinBoard director

Investors · 6

Criteria Bio VenturesBarcelona
Ben Franklin Technology PartnersreportedHarrisburg · $50K – $250K
BioAdvancereported · 2 sourcesConshohocken · $500K – $1.5M
Columbus Venture PartnersreportedValencia

Also in the syndicate · 2

Beyond CeliacSessa Capital

Funding

SEC filings, press & company announcements

$32.3M disclosed across 2 rounds · 2024–2026

▶$15.1MraisedJun 2026 · 13 investors · Biotechnology
Rule 506(b)
Tolerance Bio Raises $15.1M to Advance a New Vision for Immune Tolerance | BioBuzzbiobuzz.io · Jul 2026Tolerance Bio raises $15.1M, backers include Beyond Celiac - Philadelphia Business Journalbizjournals.com · Jul 2026
Officers, directors & promoters on the filing
  • Philip BallExecutive Officer, Director
  • Damia Tormo CarullaDirector
  • Justin VogelExecutive Officer, Director
  • Francisco LeonExecutive Officer, Director
  • Pablo CironiDirector
  • Robert GoldsteinDirector
Amount sold
$15.1M
First sale
Jun 2026
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Osmosis25 shared keywordsOsmosis is a US health education platform of short-form medical videos and learning tools, acquired by Elsevier.

Companies competing with Tolerance Bio for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Tolerance Bio has filed a notice of an exempt offering of securities to raise $15,101,584.00 in New Funding. - intelligence360intelligence360.news · Jul 2026Tolerance Bio Raises $15.1M to Advance a New Vision for Immune Tolerance | BioBuzzbiobuzz.io · Jul 2026Tolerance Bio raises $15.1M, backers include Beyond Celiac - Philadelphia Business Journalbizjournals.com · Jul 2026Beyond Celiac Investments Announces Investment in Tolerance Bio to Advance Novel Approach in Celiac Disease | BeyondCeliac.orgbeyondceliac.org · Jun 2026Tolerance Bio, Inc. Launches with $17.2 Million in Seed Financing to Advance Thymus-Based Therapies for Immune-Mediated Diseases — Tolerance Bio | | Thymus-Powered Healthspan | Immune Tolerance | Control immune tolerance at will - by restoring, preserving, and manipulating the function of the thymustolerancebio.com · Oct 2024Tolerance Bio Raises $17.2M in Seed Financingfinsmes.com · Oct 2024

Frequently asked questions

What does Tolerance Bio do?
Tolerance Bio develops therapeutics targeting the thymus—the regulator of immune tolerance—to preserve, restore, and manipulate its function and extend health span. Its work includes iPSC-derived thymic organoids and licensed interleukin-7 therapy aimed at improving thymic function and immune resilience.
Who founded Tolerance Bio?
Tolerance Bio was founded by Francisco Leon in 2023.
Who are Tolerance Bio's investors?
Tolerance Bio's investors include Criteria Bio Ventures, Ben Franklin Technology Partners, BioAdvance, Columbus Venture Partners.
How much funding has Tolerance Bio raised?
Tolerance Bio has disclosed $32.3M raised across 2 rounds.
Where is Tolerance Bio headquartered?
Tolerance Bio is headquartered in Philadelphia, US.